Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)

Pfizer

Status and phase: Completed; Phase 3

Conditions: Dermatitis, Atopic; Dermatitis; Hypersensitivity, Immediate; Genetic Diseases, Inborn; Immune System Diseases; Skin Diseases; Hypersensitivity; Eczema; Skin Diseases, Eczematous; Skin Diseases, Genetic

Treatments: Drug: Dupilumab; Drug: PF-04965842 100 mg; Drug: Oral Placebo; Drug: Injectable Placebo; Drug: PF-04965842 200 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT03720470

2018-002573-21 (EudraCT Number)

COMPARE (Other Identifier)

B7451029

Details and patient eligibility

About

B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy. The efficacy of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily will be evaluated relative to placebo over 12 weeks. The efficacy of the two dosage strengths of PF-04965842 will be compared with dupilumab in terms of pruritus relief at 2 weeks. The two dosage strengths of PF-04965842 and dupilumab 300 mg injected subcutaneously once every two weeks (with a loading dose of 600 mg injected on the first day) will also be evaluated relative to placebo over 16 weeks. The safety of the investigational products will be evaluated over the duration of the study. Subjects will use non-medicated emollient at least twice a day and medicated topical therapy such as corticosteroids, calcineurin inhibitors or PDE4 inhibitors, as per protocol guidance, to treat active lesions during the study. Subjects who are randomized to receive one of the two dosage strengths of PF-04965842 will also receive placebo injectable study drug every two weeks until Week 16 and then will continue on receiving only the oral study drug for 4 weeks. Subjects who are randomized to receive dupilumab injections every two weeks will also receive oral placebo to be taken once daily until Week 16 and will then continue to receive only the oral placebo for 4 weeks. Subjects who are randomized to the placebo arms, will receive both daily oral placebo and injectable placebo every two weeks until Week 16, after which they will receive either 100 mg or 200 mg of PF-04965842 taken orally once daily for 4 weeks, dependent upon which arm they have been allocated to. Eligible subjects will have an option to enter a long-term extension study after completing 20 weeks of treatment.

Enrollment: 838 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female subjects aged 18 years or older at the time of informed consent

• Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS severity 4)

• Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with medicated topical therapy for AD for at least 4 weeks, or who have required systemic therapies for control of their disease.

• Must be willing and able to comply with standardized background topical therapy, as per protocol guidelines throughout the study

• Female subjects who are of childbearing potential must not be intending to become pregnant, currently pregnant, or lactating. The following conditions apply:

  1. Female subjects of childbearing potential must have a confirmed negative pregnancy test prior to randomization;
  2. Female subjects of childbearing potential must agree to use a highly effective method of contraception for the duration of the active treatment period and for at least 28 days after the last dose of investigational product.

• Female subjects of non-childbearing potential must meet at least 1 of the following criteria:

  • Have undergone a documented hysterectomy and/or bilateral oophorectomy;
  • Have medically confirmed ovarian failure; or
  • Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state.

All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.

-If receiving concomitant medications for any reason other than AD, must be on a stable regimen prior to Day 1 and through the duration of the study

Exclusion criteria

• Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
• Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
• Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study
• Other active nonAD inflammatory skin diseases or conditions affecting skin
• Prior treatment with JAK inhibitors
• Previous treatment with dupilumab
• Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

838 participants in 5 patient groups, including a placebo group

PF-04965842 100 mg + Placebo Inj followed by PF-04965842 100mg

Experimental group

Description:

Once-daily oral PF-04965842 100 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 100 mg from Week 16 to Week 20

Treatment:

Drug: PF-04965842 100 mg

Drug: Injectable Placebo

PF-04965842 200 mg + Placebo Inj followed by PF-04965842 200mg

Experimental group

Description:

Once-daily oral PF-04965842 200 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 200 mg from Week 16 to Week 20

Treatment:

Drug: PF-04965842 200 mg

Drug: Injectable Placebo

Dupilumab Injection + Oral Placebo followed by Oral Placebo

Active Comparator group

Description:

Dupilumab injected subcutaneously once every 2 weeks + once-daily oral Placebo from Day 1 until Week 16 followed by once-daily oral Placebo from Week 16 to Week 20

Treatment:

Drug: Oral Placebo

Drug: Dupilumab

Oral Placebo + Placebo Inj followed by 100 mg PF-04965842

Placebo Comparator group

Description:

Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 100 mg PF-04965842 from Week 16 to Week 20

Treatment:

Drug: PF-04965842 100 mg

Drug: Oral Placebo

Drug: Injectable Placebo

Oral Placebo + Placebo Inj followed by 200 mg PF-04965842

Placebo Comparator group

Description:

Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 200 mg PF-04965842 from Week 16 to Week 20

Treatment:

Drug: Oral Placebo

Drug: PF-04965842 200 mg

Drug: Injectable Placebo